Our Pricing

How Much Weight Can You Lose On Mounjaro Timeline: What Happens

Understanding how much weight can you lose on Mounjaro helps set realistic expectations before starting treatment. Clinical trial data shows patients achieved average weight reductions of 15% to 22.5% of their starting body weight over 72 weeks, with the highest results seen on the 15mg maintenance dose [1]. At Cured Pharmacy, our UK prescribers guide patients through the full Mounjaro timeline, from initial dosing through to long-term maintenance, with transparent pricing from £135.00 and discreet delivery across the UK.

What Is Mounjaro and How Does It Work for Weight Loss?

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for chronic weight management in the UK [1]. Unlike single-pathway treatments such as semaglutide, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously, producing enhanced effects on appetite regulation, glucose metabolism, and energy expenditure.

This dual-action mechanism explains why Mounjaro consistently demonstrates superior weight loss outcomes in head-to-head clinical trials. In the SURPASS-2 study, tirzepatide 15mg resulted in significantly greater weight reduction compared to semaglutide 1mg at 40 weeks [2]. The medication works by slowing gastric emptying, reducing appetite signals in the brain, and improving insulin sensitivity, making it easier for patients to maintain a reduced-calorie diet without constant hunger.

Mounjaro is administered as a once-weekly subcutaneous injection using a pre-filled KwikPen device. Treatment begins at a low starter dose of 2.5mg weekly, with gradual increases every four weeks until reaching an effective maintenance dose between 5mg and 15mg, depending on individual response and tolerability [3]. All prescriptions require clinical assessment by a UK-registered prescriber to ensure suitability and safety.

Mounjaro Weight Loss Timeline: Week-by-Week Expectations

Weight loss on Mounjaro follows a predictable pattern, with the most dramatic results typically occurring between weeks 20 and 72 as patients reach higher maintenance doses. Understanding this timeline helps manage expectations during the initial titration phase when weight loss may feel slower than anticipated.

During weeks 1-4 on the 2.5mg starter dose, most patients experience modest weight loss of 1-2kg as the medication begins to reduce appetite and stabilise blood glucose levels. Some patients report minimal weight change during this period, which is entirely normal—the starter dose primarily serves to build tolerance and minimise gastrointestinal side effects rather than maximise weight loss [1].

Weeks 5-12 mark the dose escalation phase, where patients typically increase to 5mg and then 7.5mg if tolerated. Average weight loss during this period ranges from 5-8% of starting body weight, with appetite suppression becoming more noticeable. Many patients find portion sizes naturally decrease and cravings for high-calorie foods diminish significantly [3].

The most substantial weight loss occurs between weeks 20-72 on maintenance doses of 10mg or 15mg. In the SURMOUNT-1 trial, patients on tirzepatide 15mg achieved an average 22.5% body weight reduction by week 72, compared to 2.4% in the placebo group [1]. Patients on the 10mg dose averaged 19.5% weight loss, whilst those on 5mg maintenance achieved approximately 15% reduction. Individual results vary based on adherence to lifestyle modifications, starting BMI, metabolic factors, and prescribed dose.

Factors That Influence Your Personal Timeline

Several factors affect how much weight you lose on Mounjaro and how quickly results appear. Starting body weight plays a significant role—patients with higher baseline BMIs often experience greater absolute weight loss in kilograms, though percentage reductions remain consistent across weight categories in clinical trials [2].

Adherence to dietary changes amplifies Mounjaro's effects considerably. Whilst the medication reduces appetite and makes calorie restriction easier, patients who combine treatment with structured nutrition plans and regular physical activity consistently achieve results at the higher end of clinical trial ranges. Your UK prescriber can provide guidance on evidence-based lifestyle modifications that complement pharmacological treatment.

Age, metabolic health, medication history, and individual metabolic rate also influence outcomes. Patients with insulin resistance or type 2 diabetes may experience different weight loss patterns compared to those without metabolic complications, though tirzepatide remains highly effective across diverse patient populations [3].

Average Weight Loss Results: What Clinical Trials Show

The SURMOUNT clinical trial programme provides the most comprehensive evidence for Mounjaro weight loss outcomes in adults with obesity or overweight with weight-related complications. SURMOUNT-1, the largest trial involving 2,539 participants without diabetes, demonstrated dose-dependent weight reductions over 72 weeks [1].

Participants receiving tirzepatide 5mg achieved an average weight loss of 15% (approximately 15.6kg from a baseline of 104.8kg). Those on the 10mg dose lost an average of 19.5% (approximately 20.9kg), whilst the highest 15mg dose produced 22.5% average reduction (approximately 23.6kg). By comparison, the placebo group receiving lifestyle interventions alone lost just 2.4% (approximately 2.4kg) [1].

SURMOUNT-2 examined tirzepatide specifically in patients with type 2 diabetes and obesity, showing average weight reductions of 12.8% to 15.7% depending on dose over 72 weeks—slightly lower than the non-diabetic population but still clinically significant [4]. These results positioned tirzepatide as the most effective pharmacological weight loss intervention currently licensed in the UK.

Real-world outcomes often mirror clinical trial data when patients maintain consistent dosing schedules and follow prescriber guidance. At Cured Pharmacy, our clinical team monitors patient progress throughout treatment, adjusting doses as needed to optimise results whilst managing any side effects that may emerge.

How Much Weight Can You Lose on Mounjaro Compared to Other Treatments?

When comparing weight loss medications available through UK pharmacies, Mounjaro consistently demonstrates superior efficacy in head-to-head trials and meta-analyses. Understanding these differences helps patients and prescribers select the most appropriate treatment based on individual circumstances and weight loss goals.

Wegovy (semaglutide 2.4mg) represents the closest comparator, achieving average weight loss of 14.9% over 68 weeks in the STEP-1 trial [5]. Whilst highly effective, this falls short of tirzepatide's 22.5% average at the highest dose. Direct comparison in SURPASS-2 showed tirzepatide 15mg produced significantly greater weight reduction than semaglutide 1mg at 40 weeks, though the semaglutide dose used was lower than the 2.4mg Wegovy formulation [2].

Saxenda (liraglutide 3mg) produces more modest results, with average weight loss of 8% over 56 weeks in the SCALE trial programme [6]. As a daily injection rather than weekly administration, Saxenda may suit patients who prefer more frequent dosing with smaller individual injections, though overall efficacy remains lower than newer GLP-1 receptor agonists.

Oral medications like Orlistat work through entirely different mechanisms, blocking fat absorption in the digestive system rather than affecting appetite hormones. Clinical trials show average weight loss of 2.9kg more than placebo over one year—significantly less than injectable GLP-1 treatments but suitable for patients who cannot tolerate injections or prefer oral medication [7]. Cured Pharmacy offers the full range of licensed weight loss treatments, with prescribers selecting the most appropriate option during your clinical consultation.

Choosing Between Mounjaro and Alternative Treatments

Your UK prescriber will assess multiple factors when recommending between Mounjaro and other weight loss medications. Medical history, current medications, previous weight loss attempts, injection tolerance, budget considerations, and weight loss targets all influence treatment selection.

Mounjaro typically represents the first-line choice for patients seeking maximum weight loss efficacy who can tolerate weekly injections and meet prescribing criteria. Wegovy offers an established alternative with extensive real-world safety data and competitive pricing. Saxenda suits patients requiring daily dosing flexibility or those stepping up from oral treatments. Orlistat remains appropriate for patients preferring oral medication or those with contraindications to injectable therapies.

All prescription weight loss medications available at Cured Pharmacy require clinical assessment by a UK-registered prescriber before dispensing. Our consultation process takes under three minutes online, with prescriptions typically approved within 24 hours for eligible patients.

Managing Side Effects During Your Mounjaro Weight Loss Journey

Gastrointestinal side effects represent the most common tolerability concern with Mounjaro, affecting approximately 20-30% of patients during dose escalation phases [1]. Nausea, diarrhoea, constipation, and reduced appetite typically emerge when increasing doses but generally resolve within 1-2 weeks as the body adjusts to higher tirzepatide levels.

The gradual four-week dose titration schedule specifically aims to minimise these effects by allowing physiological adaptation before each increase. Starting at 2.5mg weekly and increasing slowly to 5mg, 7.5mg, 10mg, 12.5mg, and finally 15mg gives the digestive system time to accommodate tirzepatide's effects on gastric emptying and gut motility [3].

Practical strategies can significantly reduce gastrointestinal discomfort during treatment. Eating smaller, more frequent meals rather than large portions helps manage nausea and prevents overwhelming the slowed digestive system. Avoiding high-fat, greasy, or spicy foods during the first few days after dose increases reduces symptom severity. Staying well-hydrated and maintaining regular meal timing supports consistent medication absorption and tolerability.

Serious side effects remain rare but require immediate medical attention. These include severe persistent abdominal pain (possible pancreatitis), vision changes, signs of thyroid tumours, severe allergic reactions, or symptoms of gallbladder disease [3]. Your prescriber will review your full medical history during consultation to identify any contraindications or elevated risk factors before prescribing Mounjaro.

When to Contact Your Prescriber

Most side effects can be managed with dietary adjustments and do not require treatment interruption. However, you should contact your Cured Pharmacy prescriber if you experience persistent vomiting lasting more than 24 hours, severe abdominal pain, signs of dehydration, unexplained persistent nausea that prevents eating, or any concerning symptoms that don't resolve within two weeks of a dose increase.

Your prescriber may recommend maintaining your current dose for an additional four weeks before the next increase, temporarily reducing the dose, or switching to an alternative weight loss medication if side effects remain intolerable despite management strategies. Regular monitoring ensures treatment remains both effective and tolerable throughout your weight loss journey.

Getting Started with Mounjaro at Cured Pharmacy

Beginning Mounjaro treatment through Cured Pharmacy involves a straightforward online process designed to meet all UK regulatory requirements whilst providing convenient access to prescription weight loss medication. Our GPhC-registered pharmacy (9012511) operates under the clinical oversight of Superintendent Pharmacist Tarun Kumar (GPhC 2233073), ensuring all prescriptions meet MHRA standards and patient safety protocols.

The process begins with a free online clinical consultation taking under three minutes to complete. You'll provide information about your medical history, current medications, weight loss goals, previous weight management attempts, and any relevant health conditions. This assessment allows our UK-registered prescribers to determine whether Mounjaro is clinically appropriate and safe for your individual circumstances.

Once your consultation is reviewed and approved—typically within 24 hours—your prescription is issued and your medication is dispensed from our UK pharmacy. Mounjaro is available with transparent upfront pricing, with no hidden consultation fees or subscription requirements. Your medication arrives in 100% discreet packaging via tracked delivery, with injection technique guidance and ongoing prescriber support included throughout treatment.

Follow-up consultations occur at regular intervals to monitor progress, assess tolerability, and adjust dosing as needed. Our clinical team remains available to answer questions, provide guidance on managing side effects, and support your weight loss journey from initial prescription through to maintenance therapy. All medications supplied are genuine UK-licensed products sourced through regulated pharmaceutical supply chains, never grey-market imports or unlicensed alternatives.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
3. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen – Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/product/14443
4. Garvey, W. T., Frias, J. P., Jastreboff, A. M., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 402(10402), 613–626. https://doi.org/10.1016/S0140-6736(23)01200-X
5. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
6. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
7. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155
8. Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual weight loss results vary and depend on multiple factors including adherence to treatment, lifestyle modifications, starting weight, and metabolic characteristics. Past clinical trial results do not guarantee individual outcomes.